Flexion’s Pandemic Rebound: How Zilretta Dropped 80% But Is Still Coming Out Ahead
Executive Summary
The knee osteoarthritis injection was hit hard by COVID-19 restrictions, at first. But CEO Mike Clayman reflected in an interview about how the pandemic experience is helping fuel further growth for Zilretta.
You may also be interested in...
Pacira Aims For Non-Opioid Pipeline Growth With Flexion Buy
Flexion’s Zilretta is forecast to have big market potential with the growth of osteoarthritis, and Pacira’s CEO suggested there were commercial synergies with its Iovera device.
Bone Has Tough Path Forward After Phase III Knee Osteoarthritis Fail
The company said the study of JTA-004 failed to meet its primary and key secondary endpoints, though a post-hoc analysis indicated activity in a patient subset.
‘Business Unusual’: COVID-19 Brought Commercial Changes To Pharma And It May Stick
The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.